18-19 February, 2027 | Berlin, Germany
mrna-therapeutics-non-viral-delivery-europe.com

Free To Attend For Biopharma & Academics*

WELCOME
EXPERT SPEAKERS
AGENDA
PARTNER WITH US
REGISTER YOUR PLACE

6th Annual

mRNA-Based Therapeutics & Non-Viral Delivery Summit EUROPE

Accelerating RNA Technology & Delivery Innovation Across Modalities

Optimising Formulation & Delivery, De-Risking the Path to Clinic & Enhancing Manufacturing & Analytical Strategies to Spearhead End-to-End mRNA Therapeutic Development

Expert Speakers Include:



Bo Ying
Chief Executive Officer
Abogen Biosciences



Covadonga Pañeda
Chief Operating Officer
Altamira Therapeutics



George Thom
Director (In Vivo Expressed Biologics - mRNA)
AstraZeneca



Christian Reinsch
Vice President Technology Profiling
BioNTech SE



Constanze Ochmann-Harding
Director CMC
Epitopea Ltd.



Ansgar Santel
Chief Executive Officer & Managing Director
Pantherna Therapeutics GmbH

Proud to Partner With:

ProBio | ECLIPSEBIO THE RNA GENOMICS COMPANY | Roche | ARCALIS

+1 617 455 4188 info@hansonwade.com
www.mrna-therapeutics-non-viral-delivery-europe.com

hansonwade

Welcome to the 6th mRNA-Based Therapeutics & Non-Viral Delivery Summit Europe

Accelerating the Next Generation of mRNA Therapeutics Through Smarter Design, Targeted Delivery & Scalable Manufacturing

With advances in *in vivo* CAR-T and gene editing, alongside growing industry investment in tissue-specific LNP delivery technologies, the mRNA therapeutics field is moving towards increasingly ambitious therapeutic applications. Attention is shifting towards overcoming the challenges that will determine their clinical success, from optimising mRNA design and achieving precise tissue targeting to extending therapeutic expression, enabling repeat dosing and scaling manufacturing.

Marking a new chapter for Europe's mRNA and LNP community, the **6th mRNA-Based Therapeutics & Non-Viral Delivery Summit Europe** unites these two fields for the first time across therapeutic development, advanced drug delivery and process development & CMC in **one integrated forum** to tackle the interconnected challenges of advancing mRNA medicines towards the clinic.

Across two dedicated tracks covering **R&D & Preclinical Development** and **Process Development & CMC**, explore innovations in mRNA design and optimisation, emerging applications in *in vivo* CAR-T and gene editing, alongside practical strategies for improving tissue-specific delivery, extending therapeutic expression, optimising manufacturing and navigating evolving regulatory expectations.

Built with insights from **AstraZeneca**, **BioNTech**, **Abogen Biosciences**, **Almirall**, **Circurna**, **Pantherna Therapeutics** and more, join 100+ trailblazing experts in R&D, process development, manufacturing, and delivery from across the mRNA and LNP ecosystem. Gain access to emerging scientific data, benchmark development strategies and connect with the partners needed to accelerate the next generation of mRNA therapeutics.

Hear from Our 2027 Speakers:

> "LNPs and mRNA must be addressed together because their performance is intrinsically linked: mRNA therapeutics cannot achieve their full potential without effective delivery systems, while LNP development must be tailored to the specific requirements of the mRNA payload."
>
> **Research Analyst, Fraunhofer IMM**

Key Benefits of Attending



Three Conferences. One Unmissable Meeting: For the first time, we're bringing together the **mRNA-Based Therapeutics**, **LNP Development**, and **mRNA Process Development & CMC** Europe conferences into **one integrated summit.** The ultimate platform uniting the expertise needed to advance next-generation mRNA medicines from discovery through to the clinic.




Unlock Delivery Beyond the Liver: Explore targeted LNPs, cell-penetrating peptides and alternative non-viral carriers to improve tissue selectivity, intracellular RNA delivery and therapeutic performance with the **University of Tartu**, **Altamira Therapeutics** and **NanoGrab**.



Match mRNA Design & Delivery to Therapeutic Need: Explore strategies to extend protein expression, enable durable *in vivo* cell engineering and optimise administration routes to improve therapeutic performance across metabolic, genetic and respiratory diseases with **ScionxBio**, **CPTx** and **the University of Napoli Federico II**.



Make Innovation Manufacturable: Benchmark purification, impurity removal, formulation processing and analytical strategies to improve RNA recovery, maintain product quality and scale manufacturing towards GMP readiness with **BioNTech**, **Circurna** and **Fraunhofer IMM**.



Harness AI & Automation to Accelerate Innovation: Explore AI-driven lipid discovery, high-throughput mRNA candidate screening and automated therapeutic development to accelerate platform optimisation, improve candidate selection and reduce development costs with **CybernaX Bio** and **Abogen Biosciences**

Three Communities. One Integrated Summit.

Bringing the mRNA Therapeutics, Non-Viral Delivery & CMC Communities Together Under One Roof

For 2027, we're bringing together our established meetings covering mRNA therapeutics, LNP delivery, and mRNA process development & CMC into one integrated summit in Berlin. Recognising that advances in mRNA medicines cannot happen in isolation, this expanded programme connects therapeutic R&D, delivery and manufacturing expertise to tackle shared development challenges, exchange insights and accelerate clinical translation.

Lipid Nanoparticles Development Summit EUROPE

mRNA-Based Therapeutics Summit EUROPE

mRNA Process Development & CMC Summit EUROPE

mRNA-Based Therapeutics & Non-Viral Delivery Summit EUROPE

Looking for LNP & non-viral delivery insights?

Look out for the DELIVERY tag throughout the agenda, highlighting dedicated sessions exploring the latest advances in delivery technologies, LNP design and formulation.

More Ways to Connect & Collaborate

Make the most of your time in Berlin with **speed networking**, **interactive roundtables**, **panel discussions**, **peer exchanges** and **scientific poster sessions**. Exchange ideas, learn from others' experiences and forge valuable relationships with industry peers and potential collaborators to help advance your research and development programmes.

More Ways to Connect & Collaborate

Join Constanze Ochmann-Harding, Director CMC, Epitopea, and fellow emerging biotech leaders to share real development experiences, identify when and where to prioritise CMC investment, and compare strategies for building internal capabilities versus outsourcing.

Therapeutic Applications on the 2027 Programme

Oncology

EPITOPEA, ABOGEN, almirall, DIVINCELL, Nanograb, Pantherna Therapeutics, circio, Circurna

Rare & Genetic Diseases

AstraZeneca, circio

Respiratory Diseases

ETHRIS, cyberna, FEDERICO II, UNIVERSITY OF TARTU

Autoimmune Diseases

UNIVERSITY OF TARTU, Circurna

Cardiovascular & Metabolic

SCION X BIO, RCSI UNIVERSITY OF MEDICINE AND HEALTH SCIENCES, circio

Infectious Diseases

ABOGEN, ETHRIS, BIONTECH, sanofi, Circurna

Your Expert Speakers

Biopharma Leaders



Bo Ying
Chief Executive Officer
Abogen Biosciences



Alejandro Barquero Lemus
Regulatory Affairs Manager
Almirall



Marco Stringhini
Principal Investigator, Project Leader
Almirall



Covadonga Pañeda
Chief Operating Officer
Altamira Therapeutics



George Thom
Director (*In Vivo* Expressed Biologics - mRNA)
AstraZeneca



Yousra Yahia
Associate Principal Scientist
AstraZeneca



Abhi Kavathia
Associate Director GMP/ CMC Drug Product
BioNTech SE



Christian Reinsch
Vice President, Technology Profiling
BioNTech SE



Peter Weinstein
Chief Executive Officer
Circurna



Eoghan O'Leary
Vice President, Research
Circio AB



Matthias Bozza
Vice President, Strategy & R&D
CPTx



Pengbo Guo
Head of Product Development
CybernaX Bio



Gilles Divita
Chief Executive Officer
Divincell



Constanze Ochmann-Harding
Director CMC
Epitopea Ltd.



Philipp Schreppel
Executive Director Business Development
Ethris GmbH



Sara Carvalho
Founding Scientist
Nanograb



Heinrich Haas
Chief Technology Officer
NeoVac



Ansgar Santel
Chief Executive Officer & Managing Director
Pantherna Therapeutics GmbH



Ohad Yogev
Vice President, Discovery
ScionxBio

"The speaker lineup was excellent, with a strong balance between academic leaders and industry experts"

Chief Business Officer & CMC Lead, CybernaX Bio, 2026 Speaker

Your Expert Speakers


Academic, Research & Standards Experts



Eilien Heinrich
Research Analyst
Fraunhofer IMM



Regina Bleul
Head of Nanomedicine Group
Fraunhofer IMM



Ioannis Rabias
Head of QC
Hellenic Pasteur Institute
Member of the Group of Experts for Human Vaccines & Sera of the
European Pharmacopoeia



Chi-Kang Tseng
Associate Professor
National Taiwan University



Roland Brock
Professor of Biochemistry, Group Leader Targeted Nanomedicines
Radboud University Medical Center



Stephanie Annett
Senior Lecturer & Principal Investigator
RCSI University of Medicine & Health Science



Francesca Ungaro
Full Professor of Pharmaceutical Technology
University of Napoli Federico II



Manoj Pohare
Research Associate
University of Sheffield



Ana Rebane
Professor of Molecular Medicine
University of Tartu

"Innovation thrives when diverse expertise comes together. By uniting the mRNA and non-viral delivery community, this meeting provides a unique platform to share knowledge, identify common challenges, and leverage synergies across different modalities. These interactions can spark new ideas, strengthen collaborations, and ultimately accelerate the translation of scientific innovation into meaningful patient impact"

Associate Director GMP/CMC Drug Product, BioNTech SE, 2027 Speaker

Conference Day One
18th February 2027

7.30 **Check In & Morning Coffee**



Christian Reinsch
Vice President, Technology Profiling
BioNTech SE

8.20 **Chair's Opening Remarks**

Showcasing the Blockbuster Potential of mRNA Beyond Vaccines to Usher in a New Era of Therapeutic Value



Yousra Yahia
Associate Principal Scientist
AstraZeneca
NEW DATA

8.30 **Enabling Durable Gene Editing With Transient mRNA Delivery of Editing Machinery**

- Engineering compact CRISPR-based gene and epigenetic editors that can be efficiently delivered as mRNA *in vivo*
- Optimising mRNA architecture and delivery to achieve sufficient intracellular editor expression from a transient dose
- Demonstrating how short-lived editor expression can generate long-lasting gene silencing or therapeutic effects without requiring persistent expression

ProBio

9.00 **Session Reserved for ProBio CDMO**



Gilles Divita
Chief Executive Officer
Divincell
NEW DATA
DELIVERY

9.30 **Optimising Peptide-Based Nanoparticles for Functional RNA Delivery to Enable Therapeutic Gene Modulation & Protein Replacement**

- Leveraging AI-driven peptide optimisation to design cell-specific targeting motifs and formulate peptide-based nanoparticles without antibody conjugation or additional surface modifications
- Improving targeting specificity and reducing off-target delivery through optimised peptide-based formulations, while supporting repeat dosing for therapeutic applications
- Demonstrating the versatility of peptide-based delivery through *in vivo* data on T-cell modification for CAR-T applications and protein replacement across tumour models

10.00 **Morning Break & Speed Networking**

Join our speed networking session tailored for mRNA and delivery experts, to connect with industry peers and facilitate rapid yet meaningful exchanges of insights and expertise. Elevate your networking experience during this session designed for impactful connections among mRNA experts and stakeholders.

> "This meeting provides a great opportunity to share and discuss ideas and scientific rationales with peers in the field of mRNA therapeutics"
>
> **Chief Executive Officer, Abogen Biosciences**

Conference Day One
18th February 2027

RESEARCH & PRECLINICAL DEVELOPMENT

George Thom, Director (*In Vivo* Expressed Biologics - mRNA), **AstraZeneca**

Demonstrating Therapeutic Proof of Concept Through Preclinical & Clinical mRNA Development

11.00 Developing FKBPL mRNA Therapeutics for Obesity: From Target Biology to *In Vivo* Proof-of-Concept

- Defining the role of FKBPL in metabolic regulation and its therapeutic potential in obesity
- Addressing mRNA delivery, protein expression and formulation challenges to enable therapeutic development
- Demonstrating preclinical efficacy and outlining the next steps towards translation

Stephanie Annett, Senior Lecturer & Principal Investigator, **RCSI University of Medicine & Health Science**

NEW DATA

11.30 Targeting Respiratory Disease: Clinical Progress of ETH47, a Nasally Administered mRNA Therapeutic for Asthma

- Exploring localised respiratory delivery of therapeutic mRNA to achieve dose-dependent protein expression while minimising systemic exposure
- Evaluating the safety, tolerability and biodistribution of nasal and inhaled mRNA formulations to support therapeutic development in respiratory diseases
- Sharing Phase IIa clinical proof-of-concept findings from a rhinovirus challenge study in asthma patients, assessing therapeutic activity and symptom reduction

Philipp Schreppel, Executive Director Business Development, **Ethris GmbH**

PROCESS DEVELOPMENT & CMC

Understanding LNP Structure & Stability to Improve Formulation Performance & Product Quality

11.00 Understanding How Lipid Composition & Manufacturing Conditions Shape LNP Structure, Stability & Transfection Efficiency

- Investigating how different lipid compositions, micromixer geometries and mixing conditions influence LNP morphology, including the formation of BLEB structures
- Leveraging cryo-TEM, dynamic light scattering (DLS) and nano-flow cytometry (nanoFCM) to characterise structural differences across LNP formulations and manufacturing setups
- Demonstrating how the presence or absence of BLEB structures impacts LNP stability and *in vitro* transfection efficiency, exploring how formulation and micromixer optimisation can influence therapeutic performance

Eilien Heinrich, Research Analyst, **Fraunhofer IMM**

NEW DATA

DELIVERY

11.30 Interactive Roundtable: Overcoming mRNA-LNP Stability & Storage Challenges to Reduce Cold-Chain Dependence

An interactive discussion bringing together mRNA formulation, analytical and CMC experts to share practical approaches to:

- Improving formulation stability: Comparing liquid formulations, lyophilisation and spray drying to preserve RNA integrity, LNP structure and biological potency
- Extending shelf life & simplifying distribution: Exploring strategies to enable refrigerated (2-8°C) or room-temperature storage while minimising degradation during storage, transport and handling
- Demonstrating stability for clinical translation: Identifying critical stability-indicating attributes, analytical methods and regulatory considerations to establish shelf life and support GMP readiness

12.00 Lunch & Networking

> "Most of the mRNA field has grown up around vaccines and short-term expression. Bringing the delivery, chemistry and biology communities into one room is how the modality moves towards durable, long-acting therapeutics for chronic disease, because the advances in non-viral delivery and RNA chemistry that make sustained expression possible rarely come from any group working alone"
>
> **Vice President, Discovery, ScionxBio, 2027 Speaker**

Conference Day One
18th February 2027

Harnessing AI & Automation to Accelerate RNA & Delivery Platform Innovation

13.00 AI-Driven Next-Generation Ionisable Lipid Development & Screening Strategies for Improved Transfection Efficiency & Endosomal Escape

- Leveraging machine learning & AI-driven approaches, from foundation-model pretraining to closed-loop active learning, to accelerate novel ionisable lipid identification from limited datasets
- Addressing endosomal escape & payload–carrier compatibility through rational lipid design & formulation optimisation at reduced RNA doses
- Balancing potency, safety & developability when transitioning from research-scale to GMP-ready lipid platforms, carrying model-derived knowledge into process scale-up & CMC
- Screening novel ionisable lipid structures with multi-objective models to optimise transfection & tissue selectivity

Pengbo Guo, Head of Product Development, **CybernaX Bio**

NEW DATA
DELIVERY

13.30 Engineering Next-Generation LNPs for Precise Tissue Targeting, Repeat Dosing & Enhanced Clinical Performance

- Leveraging modular lipid architectures to tune biodistribution, pharmacokinetics, and immunogenicity across diverse therapeutic applications
- Enabling cell- and organ-specific delivery through ligand-functionalised LNP technologies to improve targeting precision and therapeutic index
- Developing LNP platforms suitable for repeat administration while maintaining favourable safety and efficacy profiles in clinical settings
- Demonstrating versatility across mRNA, saRNA, and other nucleic acid payloads to expand the therapeutic potential of LNP-enabled medicines

Heinrich Haas, Chief Technology Officer, **NeoVac**

NEW DATA
DELIVERY

14.00 Leveraging AI & Automation to Accelerate mRNA Therapeutic Development: Lessons from ABO2203 & Personalised Cancer Vaccines

- Exploring how AI-driven approaches and automated workflows can accelerate mRNA candidate discovery, platform optimisation and selection against target product profiles
- Sharing development insights from ABO2203, an mRNA-encoded CD19×CD3 T-cell engager, and Abogen's personalised cancer vaccine programmes to demonstrate how platform technologies translate into therapeutic applications
- Applying automation and AI across personalised mRNA vaccine development to reduce development timelines and lower cost of goods

Bo Ying, Chief Executive Officer, **Abogen Biosciences**

NEW DATA

Improving RNA Purity, Recovery & Scalability Through Optimised Downstream Processing

13.00 Reducing circRNA Manufacturing Costs Through Enzyme-Free Purification, Higher Yield & Scalable Processing

- Replacing reliance on RNase R, where GMP-scale supply can present cost and scalability constraints, with proprietary column chromatography to simplify circRNA processing and reduce product loss
- Increasing recovery to approximately 85% and achieving around 95% purity while scaling manufacturing towards clinical production volumes
- Scaling an enzyme-free purification process from GMP toxicology material towards 30-50 g production while maintaining yield, purity and process simplicity
- Connecting higher yield, simpler purification and lower cost of goods with more affordable RNA therapeutics and broader patient access

Peter Weinstein, Chief Executive Officer, **Circurna**

NEW DATA

13.30 Designing Scalable Purification Strategies That Preserve RNA Integrity Across Increasingly Complex RNA Constructs

- Implementing chromatography, tangential flow filtration & affinity-based methods for high-purity circRNA
- Addressing challenges in removing double-stranded RNA to meet regulatory specifications & reduce immunogenicity
- Optimising purification processes to maximise yield whilst achieving target purity levels
- Overcoming bottlenecks in downstream processing when transitioning from research to GMP scale

Chi-Kang Tseng, Associate Professor, **National Taiwan University**

NEW DATA

14.00 Developing Scalable mRNA-LNP Formulation, Purification & Process Technologies to Accelerate Clinical Translation

- Enabling both scale-up for larger production volumes and scale-down for individualised therapies
- Leveraging microtechnology-based tangential flow filtration (TFF) for small-scale RNA and LNP purification and concentration, while minimising particle loss and preserving product quality
- Combining machine learning, predictive modelling and process knowledge to optimise mixing parameters, predict target LNP size and reduce consumption of expensive materials

Regina Bleul, Head of Nanomedicine Group, **Fraunhofer IMM**

NEW DATA
DELIVERY

Conference Day One
18th February 2027

14.30 Poster Session & Afternoon Break

This poster session is your go-to session to obtain competitive insights and present your most innovative work to mRNA and delivery thought leaders and stakeholders. For more information or to submit your abstract, please email info@hansonwade.com

Aligning Product Quality, Manufacturing & Regulatory Strategies for Clinical Translation



Ioannis Rabias
Head of QC
Hellenic Pasteur Institute
Member of Experts
European Pharmacopoeia for Vaccines
NEW DATA

15.30 Leveraging Established mRNA Vaccine Quality Standards to Guide the Transition into Emerging mRNA Therapeutics

- Distinguishing drug-substance CQAs from drug-product CQAs to clarify where controls need to be applied
- Setting phase-appropriate specifications that evolve from Phase I through later-stage development
- Determining what level of heterogeneity is acceptable without compromising safety, potency or manufacturability

ECLIPSEBIO THE RNA GENOMICS COMPANY

16.00 Session Reserved for Eclipsebio

16.30 Panel Discussion: Navigating Evolving Regulatory Expectations as mRNA Moves Beyond Vaccines

- Clarifying EMA & MHRA expectations for mRNA drug substance, drug product, biodistribution, toxicology & immunogenicity as therapeutic applications diversify
- Understanding how regulatory requirements differ across vaccines, protein replacement, oncology, gene editing & other emerging mRNA applications
- Addressing the regulatory classification of mRNA products, including where non-genome-altering mRNA and mRNA-enabled gene editing fit within existing frameworks
- Keeping pace with evolving global guidance while identifying where RNA-specific regulatory expectations remain unclear



Alejandro Barquero Lemus
Regulatory Affairs Manager
Almirall



Abhi Kavathia
Associate Director GMP/CMC Drug Product
BioNTech SE



Christian Reinsch
Vice President, Technology Profiling
BioNTech SE

17.15 Chair's Closing Remarks

17.20 End of Conference Day One

> "Bringing together stakeholders from different areas with different expertise with perspectives on the same topic enables earlier interaction, better alignment of future technology developments, and faster overall progress"
>
> **Chief Executive Officer & Managing Director, Pantherna Therapeutics GmbH, 2027 Speaker**

Conference Day Two
19th February 2027

7.00 Check In & Morning Coffee

7.50 Chair's Opening Remarks

Strengthening the Scientific & Commercial Foundations for Next-Generation mRNA Therapeutics

8.00 **Panel Discussion: Positioning mRNA Programmes to Attract Investment & Strategic Partnerships**

- Addressing investor expectations: balancing early-stage innovation with clinical validation requirements
- Understanding how political & regulatory headwinds impact RNA therapeutic investment (vaccine hesitancy, government funding changes)
- Navigating the tension between long-term scientific development & short-term investor exit timelines



Ansgar Santel
Chief Executive Officer
Pantherna Therapeutics GmbH



Philipp Schreppel
Senior Director Business Development
Ethris GmbH



Bo Ying
Chief Executive Officer
Abogen Biosciences

Engineering & Evaluating mRNA Delivery Systems to Improve Therapeutic Performance



Covadonga Pañeda
Chief Operating Officer
Altamira Therapeutics
NEW DATA

8.45 **Advancing Extrahepatic RNA Delivery Through Modular Peptide-Based Nanoparticles for Emerging Therapeutic Applications**

- Enabling extrahepatic delivery to the tumour microenvironment using peptide-based nanoparticles
- Optimising the modularity and flexibility of peptide-based delivery systems to improve tissue selectivity and expand targeting capabilities
- Evaluating emerging oncology applications of non-viral delivery platforms, including preclinical approaches to assessing therapeutic performance and tissue distribution

Roche

9.15 Session Reserved for Roche



Roland Brock
Professor of Biochemistry, Group Leader Targeted Nanomedicines
Radboud University Medical Center
NEW DATA
DELIVERY

9.25 **Advanced Nanoparticle Characterisation & Tissue-Level Models to Improve Therapeutic Performance**

- Evaluating how LNP composition and targeting strategies influence biodistribution, cellular uptake and off-target exposure across preclinical models
- Improving peptide-based nanoparticle activity through formulation optimisation, using cryo-electron microscopy (cryo-EM) to understand particle morphology and structure-activity relationships
- Investigating endosomal escape and cellular trafficking using quantitative live-cell microscopy to understand how nanoparticle structure influences transfection efficiency
- Leveraging tissue-on-a-chip models to evaluate nanoparticle penetration, tissue retention and cell-specific transfection before progressing into animal studies

10.00 Morning Break & Networking

Conference Day Two
19th February 2027

RESEARCH & PRECLINICAL DEVELOPMENT

Advancing Alternative Carriers & Targeted LNP Technologies for Cell & Tissue-Specific RNA Delivery

11.00 Enabling Tissue- & Cell-Specific mRNA Delivery with Cell-Penetrating Peptide-Based Hybrid Nanosystems

- Optimising cell-penetrating peptides and hybrid nanoparticle-RNA interactions to achieve stable complexation, cellular uptake & intracellular cargo release
- Engineering peptide-based systems for selective delivery to specific tissues or cell populations
- Comparing targeting performance, tolerability, scalability & manufacturability against established LNP platforms
- Identifying applications where alternative delivery vehicles can provide a meaningful targeting or therapeutic advantage over LNPs

Ana Rebane, Prof of Molecular Medicine, **University of Tartu**

NEW DATA

DELIVERY

11.30 Developing Cell-Specific or Organ-Specific Delivery Using Targeting Ligands & Surface Modifications to Avoid Off-Target Toxicity

- Leveraging biophysics-informed AI to design combinations of peptide binders for cell-specific LNP targeting, moving beyond conventional single-receptor approaches
- Conjugating targeting moieties such as ligands, antibodies & short linear peptides to LNP surfaces to achieve cell-specific or tissue-specific delivery
- Developing scalable, multi-peptide LNP targeting strategies to enable extrahepatic mRNA delivery across different cell types and therapeutic applications

Sara Carvalho, Founding Scientist, **Nanograb**

NEW DATA

DELIVERY

PROCESS DEVELOPMENT & CMC

Aligning Analytical, Quality & CMC Strategies with Emerging RNA Therapeutic Requirements

11.00 Developing Analytical & Potency Assays That Connect Product Quality to Biological Function

- Sharing learnings of how preclinical data can link to clinical functionality
- Exploring how different RNA therapeutics have different assumptions on clinical functionality and how to translate that into assays (e.g. personalised vs gene replacement etc.)
- Incorporating these considerations early in the preclinical thought process and early-stage clinical development
- Differentiating mode-of-action assays from simple protein expression readouts: demonstrating clinical relevance

Constanze Ochmann-Harding, Director CMC, **Epitopea Ltd.**

NEW DATA

11.30 Adapting CMC & Quality by Design for Individualised mRNA-LNP Therapies

- Applying phase-appropriate CMC strategies to enable the efficient development and clinical translation of individualised mRNA-LNP therapies
- Leveraging Quality by Design (QbD) principles to build product and process understanding while maintaining flexibility for patient-specific treatments
- Addressing comparability, control strategy, and regulatory considerations in the evolving landscape of personalised medicines

Abhi Kavathia, Associate Director GMP/CMC Drug Product, **BioNTech SE**

12.00 Lunch & Networking

Conference Day Two
19th February 2027

Aligning Expression Duration, Dosing and Administration Strategies with Therapeutic Needs to Reduce Patient Burden

13.00 Long-acting xRNA for Durable, Combination Peptide Therapy in Chronic Metabolic Disease

- The modality: xRNA, a chemically modified long-acting RNA encoding protein and peptides, with durability designed in rather than added by the dosing schedule
- Durability: single-dose expression sustained for weeks; in NHP, peptide and RNA still present at ~25 days, pointing to a dosing interval of around a month
- Combination by design: multiple single-payload xRNA molecules combined at a defined, adjustable ratio and delivered as one product
- Preclinical efficacy: the four-molecule multi-agonist improved weight, glucose and liver function in obesity and MASH models, beating single and triple agonists and, weekly, daily semaglutide
- Takeaway: long-acting xRNA turns encoded peptides into durable, combination cardio-metabolic therapies

Ohad Yogev, Vice President, Discovery, **ScionxBio**

NEW DATA

13.30 Advancing Durable *In Vivo* CAR-T Cell Engineering Through Non-Viral DNA & mRNA Co-Delivery

- Optimising co-encapsulation of single-stranded DNA and mRNA within targeted lipid nanoparticles to enable efficient delivery of both nucleic acids into the same cell
- Leveraging single-stranded DNA to address immunogenicity challenges associated with conventional double-stranded DNA delivery while enabling more durable genetic modification
- Demonstrating the flexibility of non-viral genome engineering through site-specific gene integration and multi-gene delivery strategies, supported by preclinical therapeutic data

Matthias Bozza, Vice President, Strategy & Development, **CPTx**

DELIVERY

Prioritising CMC Investments & Manufacturing Strategies to Support Scalable RNA Development

13.00 Emerging Biotech Peer Exchange: Building CMC Strategies with Limited Resources

For emerging RNA developers, deciding where to invest limited CMC resources can be just as challenging as the technical development itself.

Designed as an informal, networking session, this peer exchange offers early-stage biotech teams the opportunity to connect with others facing similar challenges, share lessons learned and exchange practical advice in an open, collaborative setting.

An interactive discussion for early-stage mRNA developers to compare how they are:

- Deciding when to invest in internal CMC capabilities versus external support
- Prioritising spend across process development, assay development and regulatory preparation
- Selecting CDMOs and consultants that understand the needs of smaller companies
- Avoiding early development decisions that create expensive problems later

Constanze Ochmann-Harding, Director CMC, **Epitopea Ltd.**



14.00 Advancing RNA Nanomedicine for Delivery to Challenging Tissues: Focus on the Lung

- Designing polymeric nanocarriers for the delivery of RNA therapeutics to treat complex respiratory diseases
- Exploring nebulizer-based delivery strategies for RNA therapeutics and targeted local delivery to the lung
- Advancing the manufacturing of inhalable RNA nanomedicines from the lab toward clinical-scale production

Francesca Ungaro, Full Professor of Pharmaceutical Technology, **University of Napoli Federico II**

NEW DATA

DELIVERY

14.00 Building Continuous & Modular mRNA Manufacturing Platforms to Improve Flexibility, Contamination Control & Cost Efficiency

- Using closed systems to reduce contamination risk and manual intervention
- Building modular IVT, purification and LNP manufacturing operations that can flex between products and scales
- Standardising equipment and process controls to simplify transfer between manufacturing sites
- Understanding where modular manufacturing genuinely improves cost, speed and flexibility versus traditional fixed facilities

Manoj Pohare, Research Associate, **University of Sheffield**

NEW DATA

DELIVERY

14.30 Afternoon Break & Networking

Conference Day Two
19th February 2027

Shaping the Next Generation of mRNA Therapeutics Through Emerging Modalities & High-Value Clinical Applications



Peter Weinstein
Chief Executive Officer
Circurna
NEW DATA

15.00 Employing circRNA Durability to Sustain Therapeutic Protein Expression in Fibrosis

- Demonstrating sustained circRNA-driven protein and peptide expression in fibrosis to explore where greater durability can reduce repeat administration and improve therapeutic effect
- Leveraging microneedle patch delivery into the dermis to generate strong immune responses at lower RNA doses while enabling simpler, potentially at-home administration
- Comparing circRNA with conventional linear mRNA across therapeutic and vaccine applications to understand how expression duration, dose and route of administration translate into reduced treatment burden



Eoghan O'Leary
Vice President of Research
Circio AB

15.30 Harnessing circRNA Stability to Increase Expression, Reduce Dose & Expand into *In Vivo* CAR-T

- Potent, durable expression - circVec harnesses the intrinsic stability of circular RNA to accumulate transcripts intracellularly, delivering more protein per vector and sustaining expression far longer than conventional mRNA-based systems
- Dose-sparing AAV gene therapy - by amplifying expression per vector genome, circVec enables robust therapeutic output at substantially lower AAV doses, with dose reduction demonstrated in both heart and eye - offering the potential to widen the therapeutic window and reduce dose-related toxicity
- Expanding *in vivo* CAR-T using targeted LNPs and cell-specific expression to improve immune-cell targeting

16.00 Panel Discussion: Defining the Most Valuable Use Cases for mRNA-LNP Therapeutics: Prioritising Applications with the Greatest Clinical & Commercial Potential

- Identifying "sweet spots" for mRNA-LNP therapeutics based on dosing frequency, administration route & immune considerations
- Focusing development on validated applications: Cancer vaccines, infectious disease vaccines, protein replacement & *in vivo* CAR-T
- Learning from clinical setbacks to understand biological & commercial limitations of the platform



Christian Reinsch
Vice President Technology Profiling
BioNTech SE



Marco Stringhini
Principal Investigator, Project Leader
Almirall



Ansgar Santel
Chief Executive Officer
Pantherna Therapeutics GmbH



Gilles Divita
Chief Executive Officer
Divincell

16.45 Chair's Closing Remarks

16.50 End of Conference Day Two

2026 Partners

Lead Partner

ProBio

Expertise Partner

ECLIPSEBIO
THE RNA GENOMICS COMPANY


Innovation Partner

Roche

Exhibition Partner

ARCALIS

Get Involved



Rakkan Said
Senior Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

One Expanded Platform. Greater Partner Opportunities.

mRNA-Based Therapeutics & Non-Viral Delivery Summit EUROPE

18-19 February, 2027 | Berlin, Germany

Meet mRNA Therapeutic Developers, Delivery Innovators & CMC Decision-Makers in One European Forum

With clinical advances and growing investment across mRNA-LNP therapeutics, biopharma developers are actively seeking partners to accelerate their pipelines. The **6th mRNA-Based Therapeutics & Non-Viral Delivery Summit Europe** connects you with 100+ industry experts shaping technical requirements, evaluating technology partners and moving products toward the clinic.

Access the mRNA & Delivery Community in One Place

Connect with biopharma leaders and scientific decision-makers across mRNA therapeutics, *in vivo* cell engineering, mRNA-LNP delivery, process development, CMC, analytical development, QC and manufacturing. Meet audiences whose decisions increasingly depend on shared payload, delivery and product-quality considerations.

Demonstrate Your Technical Value

Position your capabilities against critical RNA development bottlenecks, from **sequence design, synthesis, impurity control and purification to targeted delivery, formulation, potency testing, stability and GMP manufacturing**. Use relevant sessions and scientific discussions to demonstrate how your technologies and services can improve product quality, accelerate development and support clinical translation.

Build Relevant Commercial Relationships


Use focused networking across the two main-conference streams to identify programmes needing external capabilities, understand changing buying priorities and develop partnerships spanning the RNA development value chain.

Seniority of Attendees



- C-Level / VP 24%
- Director / Head 13%
- Managers 33%
- Scientists / Team Leads / Academics 21%
- Other 8%


Type of Companies Attending



- Pharma / Biotech
- Service Providers
- Academia & Research Institutes
- Other

*Statistics Taken from 5th mRNA-Based Therapeutics Summit Europe

Get Involved



Rakkan Said
Senior Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

+1 617 455 4188 info@hansonwade.com
www.mrna-therapeutics-non-viral-delivery-europe.com

hansonwade

Ready to Register?

3 Easy Ways to Book

mrna-therapeutics-non-viral-delivery-europe.com/take-part/register/

Tel: +44 (0)20 3141 8700

Email: info@hansonwade.com

DISCOVER how mRNA therapeutics, circRNA and non-viral delivery technologies are being applied to emerging indications, from personalised oncology to protein replacement for metabolic regulation, and assess what the newest evidence means for your programme.

SOLVE shared technical hurdles in tissue targeting, intracellular delivery, immunogenicity, expression durability, scale-up, impurity control, analytics and GMP-readiness by learning directly from specialists across R&D, delivery and CMC.

CONNECT with the European mRNA ecosystem in one place, bringing therapeutic developers, delivery scientists, process and manufacturing teams, regulators and technology partners together to build collaborations that advance RNA medicines.

Drug Developer Pricing**	
Conference Only	**FREE***

Registration is FREE* if you work for a drug developer organization, research institution, or are a full-time academic.

*Please note that credit card details will be taken upon registration, and a nominal fee of €0.50 charged.

**A drug developer must have a pipeline candidate and must not be outsourcing their pipeline or offer paid for products and/or partnering services. Free access is granted upon confirmation of eligibility.

Hanson Wade retain the right to reject or cancel your registration if eligibility criteria are not met, and a paid registration will then be required to access the event.

Hanson Wade reserves the right to charge free-access guests a non-refundable charge of €100 if they do not attend the entire event or if they fail to give 7 working days' notice of nonattendance.

Please visit the website for full pricing options or email info@hansonwade.com

Service & Solution Provider Pricing***	Register & Pay By Friday 11th December	On the Door Price
Conference Only	€2,999	€3,499

***Vendor and service provider pricing refers to all employees from raw materials providers, mRNA synthesis services, CDMO/manufacturing services, formulation, stability and delivery, analytical development services, and nanoparticle platforms without internal pipelines that partner with and provide products or services to drug developers and/or research organisations.

Please note: If you are a UK or EU-based company, you may be subject to 19% VAT in addition to the price advertised. If you qualify for a reverse charge, you will have the option to provide your VAT number and the charge will be automatically deducted at checkout.

Team Discounts****

- **10% discount – 2 Attendees**
- **15% discount – 3 Attendees**
- **20% discount – 4+ Attendees**

****Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com



Venue

Hotel MOA Berlin
Stephanstraße 41 · 10559 Berlin
For further information or assistance, please visit: https://moa.de/

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade Conferences Limited is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Conferences Limited, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom